Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032799 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 905
- Enrollment target
NCT00032799: Completed Phase 3 study, sponsored by Biogen.
NCT00032799 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 905 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032799, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 905 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
Interventions
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 905 participants |
| Start Date | 2001-12 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
What the finished NCT00032799 record still lists
NCT00032799 is an interventional study that assigns participants to a tested intervention. The registered 905 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 1 intervention - of which natalizumab is the first listed.
NCT00032799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00032799 about?
NCT00032799 is a clinical study titled "Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease". The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought ...
What is the current status of trial NCT00032799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 905 participants. The study started on 2001-12. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00032799?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT00032799?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00032799's enrollment target sits among peer trials
905 347th of 2000 higher than 1,653 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia